Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154691 | 0.82 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL203099 | 0.80 | LMNA (0.39) | TSHRALDH1A1 | |
| SCHEMBL11538765 | 0.78 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL19759001 | 0.75 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL7847493 | 0.75 | TSHR (0.46) | TSHRALDH1A1 | |
| SCHEMBL20708377 | 0.75 | LMNA (0.39) | ALDH1A1 | |
| SCHEMBL11076777 | 0.74 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL24465045 | 0.74 | — | — | |
| SCHEMBL11245204 | 0.72 | LMNA (0.40) | TSHRALDH1A1 | |
| SCHEMBL135497 | 0.72 | LMNA (0.44) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-02-25 | — | — | US | disclosed |
| EP-1505965-B1 | USE OF THE METABOLITE OF VALSARTAN TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | MALININ ALEX (US) | 2005-09-08 | — | — | US | disclosed |
| EP-1505965-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094915-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | PDGFRA, PLAT, PTAFR | TSHR 2190/4885ALDH1A1 796/4885TP53 4336/4885 |
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | PTAFR, PDGFRA, ACE | TSHR 1330/4885ALDH1A1 1036/4885TP53 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.